MUMBAI, Nov. 6 -- Nandini Piramal, chairperson of Piramal Pharma, speaking to reporters on Thursday, said a rebound in US biopharma funding could boost future orders, even as the company on Wednesday reported a 9% fall in Q2FY26 revenues, hit by a sharp decline in its contract manufacturing business.

The company reported a net loss of Rs.99 crore for the quarter, compared with a profit of Rs.23 crore in the same period last year, while its Ebitda margin shrank to 11% from 18% in Q2FY25.

The CDMO (contract development and manufacturing) segment, the company's largest revenue driver, posted a 21% year-on-year (YoY) decline to Rs.1,044 crore, primarily due to inventory destocking by a key client ahead of a product launch.

"There has been ...